[Toward individualized immunosuppression].
Grinyó
J M
JM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002648:Child; D018849:Controlled Clinical Trials as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D014644:Genetic Variation; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006131:Growth Inhibitors / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors / Q000276:immunology; D014019:Tissue Donors
D000911:Antibodies, Monoclonal; D000963:Antimetabolites; D065095:Calcineurin Inhibitors; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2